Eli Lilly (LLY)

One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.

These elite businesses could help you build lasting wealth.

The weight-loss drugs are growing in popularity and altering consumer behavior in significant ways.

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

UBS analyst Michael Yee called Novo Nordisk a value trap, but still sees a turnaround playing out over time.

Grail and Veeva Systems could be well insulated from near-term headwinds.

Eli Lilly's obesity lead is only the starting point. See what its pipeline, manufacturing build-out, pricing pressure, and earnings trajectory could mean for the stock's next chapter.

Stansberry Research's Whitney Tilson argues record highs mask a bifurcated market, favoring Joby Aviation, Casey's General Stores, and Eli Lilly as value picks outside the AI trade.

Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.

The company is far from a one-trick pony.

People have long been willing to pay for healthcare despite rising costs, with Medtronic and Eli Lilly offering two different angles on the space.

Novo Nordisk has a huge opportunity in GLP-1 weight-loss drugs, but it has to prove it can use that success to build for the future.

Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include: Conexeu Sciences Inc. (Nasdaq: CNXU), Solventum Corporation (NYSE: SOLV), Vericel Corporation (Nasdaq: VCEL), Axogen, Inc. (Nasdaq: AXGN), Eli Lilly and Company (NYSE: LLY).

U.S. healthcare stocks delivered 28.8% gains over one year versus 22.5% for international peers. Both funds carry nearly identical expense ratios and low volatility profiles.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.

Eli Lilly is partnering with Ginkgo Bioworks on drug discovery.

Owning a low-cost index fund is one of the simplest ways to build wealth in the stock market over the long term.

Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.